The disintegration of tablets plays a crucial role in facilitating drug release, and disintegrants are used in tablet formulations to promote the disintegration process. This study aimed to explore and understand the impact of salt incorporation on tablet disintegratability. The study was designed to modulate the microenvironment temperature of tablets through dissolution of salts incorporated in the formulation, with the aim to facilitate tablet disintegration. It was observed that the incorporation of salts generally prolonged tablet disintegration. The impact of incorporating salts on tablet properties was both concentration-dependent and multi-factorial. The observed effect of salts on tablet disintegration was likely influenced by a combination of factors, including different properties of the salts, enhanced solubility of components, the temperature difference between the tablet and the disintegration medium, the expansion of air resulting from increased microenvironment temperature, and the competition for water between salts and disintegrants. These factors collectively contributed to the overall impact of salts on tablet disintegration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijpharm.2023.123759 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Development of an Age-Appropriate Fixed Dose Combination for Tuberculosis Using Physiologically-Based Pharmacokinetic Modeling (PBBM) and Risk Assessment.
Pharmaceutics
December 2024
Simulations Plus, Inc., 42505 10th Street West, Lancaster, CA 93534-7059, USA.
The combination of isoniazid (INH) and rifampicin (RIF) is indicated for the treatment maintenance phase of tuberculosis (TB) in adults and children. In Brazil, there is no current reference listed drug for this indication in children. Farmanguinhos has undertaken the development of an age-appropriate dispersible tablet to be taken with water for all age groups from birth to adolescence.
View Article and Find Full Text PDFEffectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study).
J Headache Pain
January 2025
Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
Background: Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life effectiveness and tolerability. GAINER, a prospective, multicentric study, aimed to evaluate rimegepant effectiveness and tolerability in the real-world setting.
View Article and Find Full Text PDF[Development of fast dissolving sublingual immunotherapy tablet enhancing medication accessibility].
Nihon Yakurigaku Zasshi
January 2025
Torii pharmaceutical Co., LTD.
In the overall Japanese population, the prevalence of perennial allergic rhinitis (AR) increased from 18.7% to 24.5% from 1998 to 2019.
View Article and Find Full Text PDFSurvival after aluminum phosphide poisoning with cardiotoxicity: a case report.
J Med Case Rep
December 2024
Department of Internal Medicine, Woldia Comprehensive Specialized Hospital, Woldia, Ethiopia.
Introduction: Aluminum phosphide is a cheap and commonly used rodenticide that is also an effective solid fumigant and frequently used for grain preservation. The pill contains around 44% inert elements (ammonium carbonate) to avoid disintegration of the tablet, while the rest (about 56%) is aluminum phosphide. Because it is freely available on the market, it is one of the commonly used agents for self-poisoning in different parts of the developing world.
View Article and Find Full Text PDFDevelopment of immediate release tablet formulations of lornoxicam with hot melt extrusion-based three-dimensional printing technology.
Drug Dev Ind Pharm
January 2025
Faculty of Pharmacy, Department of Pharmaceutical Technology, Gazi University, Etiler, Turkey.
Introduction: This study aims to develop immediate release tablet formulations of lornoxicam (LRX) using hot melt extrusion (HME)-based fused deposition modeling (FDM) focusing on the adjustment of drug release by arranging infill densities and evaluating microcrystalline cellulose II (MCC II) as a disintegrating agent for HME-FDM purposes. LRX is a poorly soluble drug that exhibits pH-dependent solubility with a high thermal degradation temperature. These characteristics make it an ideal model drug for the HME-based FDM technique.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!